The MCCC considers the Developmental Funds as one of the most critical components of CCSG support. Together with institutionally derived MCCC discretionary funds and the annual grant support from the Fraternal Order of Eagles, these funds have supported recruitment of new research faculty, shared resource development, and the initiation of research projects or generation of pilot data for subsequent peer review grant applications. Given the small size of the CCSG Developmental Fund pool relative to the substantial expansion realized over the last funding period, institutionally-derived MCCC discretionary funds and philanthropic sources have contributed more than 90% of the funding needed for pilot projects, program or shared resource initiation, and all funding for instrumentation and new laboratory set-up costs. Processes are firmly established in the MCCC to solicit and review proposals for CCSG Developmental Fund support. Funding is predicated on scientific merit, programmatic relevance, MCCC strategic priorities and, in the case of shared resource development, the unambiguous need of peer review investigators. An increase in Developmental Funds is requested in this application, though it is commensurate with the funding level recommended for the current funding period (but not awarded). These Developmental Funds will be leveraged with institutionally derived MCCC discretionary funds. Funding is requested in the next project period to support initiatives in the following categories: ? Continued recruitment of outstanding new research faculty - the MCCC is currently actively recruiting to fill 20 positions across its three campuses ? Pilot projects - to enable the MCCC to pursue outstanding science leading to peer review funding; including highly innovative but high-risk proposals that might otherwise not receive funding ? Development of shared resources - to insure the scientific vitality of MCCC investigators and programs The MCCC's Developmental Fund request represents approximately 8% of the direct costs requested. The MCCC has a proven track record in stewardship of these funds as evidenced by the 'return on investment'of new faculty recruited to the center during the current grant period. The current request, substantially buttressed by the continued commitment of MCCC discretionary funds, will enable the Director to support activities critical to the sustained research excellence of this Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465650
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$330,609
Indirect Cost
$101,734
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Li, Mulin Jun; Li, Miaoxin; Liu, Zipeng et al. (2017) cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes. Genome Biol 18:52
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Patnaik, Mrinal M; Barraco, Daniela; Lasho, Terra L et al. (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542-548
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Russell, Stephen J; Peng, Kah-Whye (2017) Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther 25:1107-1116
Pathangey, Latha B; McCurry, Dustin B; Gendler, Sandra J et al. (2017) Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget 8:10785-10808
Peacock, Justin G; Harmsen, William S; Link, Michael J et al. (2017) Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 78:68-74
Ertz-Archambault, Natalie; Kosiorek, Heidi; Taylor, Gretchen E et al. (2017) Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 3:936-943
Zhou, Dan; Hlady, Ryan A; Schafer, Marissa J et al. (2017) High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver. Epigenetics 12:55-69
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393

Showing the most recent 10 out of 1086 publications